Eton Pharmaceuticals Files 8-K for 'Other Event' and Financial Exhibits
Ticker: ETON · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1710340
Sentiment: neutral
Topics: 8-K filing, corporate-event, regulatory-filing
TL;DR
**Eton Pharma just dropped an 8-K for an 'Other Event' and financials, so keep an eye out for details!**
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on February 21, 2024, reporting an "Other Event" and "Financial Statements and Exhibits." The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported also on February 21, 2024. The company, based in Deer Park, Illinois, operates under the pharmaceutical preparations industry.
Why It Matters
This filing signals that Eton Pharmaceuticals has an event or information deemed significant enough to warrant immediate disclosure, which could impact investor perception and future company direction.
Risk Assessment
Risk Level: medium — The filing itself is administrative and does not contain specific details about the 'Other Event' or financial information to assess risk.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- Deer Park, Illinois (location) — Company headquarters
- February 21, 2024 (date) — Date of report and earliest event reported
- 001-38738 (other) — Commission File Number
- 37-1858472 (other) — I.R.S. Employer Identification Number
FAQ
What is the purpose of this 8-K filing by Eton Pharmaceuticals, Inc.?
The 8-K filing by Eton Pharmaceuticals, Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting an "Other Event" and "Financial Statements and Exhibits."
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 21, 2024.
What is the business address of Eton Pharmaceuticals, Inc.?
The business address of Eton Pharmaceuticals, Inc. is 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is Eton Pharmaceuticals, Inc.'s Commission File Number?
Eton Pharmaceuticals, Inc.'s Commission File Number is 001-38738.
In which state is Eton Pharmaceuticals, Inc. incorporated?
Eton Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-02-21 06:55:25
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20240219_8k.htm (8-K) — 25KB
- ex_628296.htm (EX-99.1) — 7KB
- 0001437749-24-004936.txt ( ) — 163KB
- eton-20240221.xsd (EX-101.SCH) — 3KB
- eton-20240221_def.xml (EX-101.DEF) — 11KB
- eton-20240221_lab.xml (EX-101.LAB) — 15KB
- eton-20240221_pre.xml (EX-101.PRE) — 11KB
- eton20240219_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 21, 2024, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the United States Patent and Trademark Office ("USPTO") has granted the Company's U.S. Patent Application No. 18/113,458, which covers the Company's ET-400 product candidate's proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 and is expected to be listed in the FDA's Orange Book upon the product's approval. The Company has additional patent applications related to the product under review with the USPTO. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit 99.1 Press Release dated February 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 21, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3